Public-company intelligence, source by source
A free email briefing on public NWBO and DCVax developments, with source links and clear labels for what is supported and what remains unverified.
Free NWBO briefing
Filings, trials, court updates, and meaningful community claims in one source-aware briefing.
Free: weekdays at 9:00 AM and 6:00 PM ET, weekends at 9:00 AM ET. Enhanced: weekdays at 9:15 AM and 6:15 PM ET, weekends at 9:15 AM ET
Public archive
No confirmed news, 5 community topics from an owner-requested Free addendum research pass that reran coverage for the window of the edition scheduled for October 16, 2026 at 6:00 PM EDT. Coverage gaps are disclosed.
Covered October 16, 2026 at 8:50 AM EDT through October 18, 2026 at 6:58 PM EDTThe source surface
Primary records can confirm a development. Community and discovery sources can identify leads that still require verification.
Company announcements, filings, publications, and corporate updates from NWBio.
Open source10-K, 10-Q, 8-K, registration, ownership, and other filings for CIK 0001072379.
Open sourceStudy registrations, status changes, sponsors, interventions, and posted results.
Open sourceUK regulator guidance and public records relevant to medicines and marketing authorization.
Open sourcePublic docket metadata and available RECAP documents for NWBO-related litigation.
Open sourcePatent applications, grants, and prosecution records tied to relevant NWBO entities.
Open sourceInternational patent publication and application records for relevant entities and technologies.
Open sourceAuthorized read-only public-index discovery for NWBO and DCVax discussion; not proof of a material claim.
Open sourcePublic community discussion and market context, retained separately from verified company records.
Open sourcePublic manual review of investor discussion and resurfaced claims.
Open sourceEvidence before interpretation
Supported directly by a primary record or named counterparty.
A statement made by NWBio that may still need independent context.
An SEC filing, regulator action, docket, or other official record.
Independent reporting with identifiable sourcing and editorial accountability.
A trial, publication, conference, or scientific record with a clear NWBO connection.
Discussion worth checking, not evidence that a claim is true.
A material claim that could not be confirmed from reliable sources.
Available evidence did not support the claim as stated.
Accurate context that is resurfacing but is not a new development.
A transparent correction attached to the affected edition or claim.
Enhanced rollout
The Free Monitor remains account-free on its existing schedule. The separate $7/month Enhanced Monitor adds account controls and lets subscribers choose the fixed first, second, and weekend Eastern delivery windows.
X remains discovery evidence. Material claims still require primary or reputable non-X corroboration before they appear as confirmed or credibly reported.
Current status: Accounts, billing, paid research, and delivery are implemented behind independent safety controls.
The former interest poll is closed. Public Enhanced enrollment is now open.
Account registration does not charge you. After email verification, Stripe shows the recurring plan before you decide whether to complete checkout.
Create your account for the $7/month plan, verify your email, then review the secure Stripe checkout.
Create Enhanced accountNo charge is created by opening or registering an account.
This monitor organizes public information and authorized read-only community sources. It is not affiliated with Northwest Biotherapeutics and is not investment or medical advice.
Apptillion